Adolore Biotherapeutics, Inc.: Adolore Biotherapeutics Enters into Exclusive License Agreement with University of Pittsburgh for Patents Protecting Non-Toxic Replication-Defective HSV Vectors for Efficient Gene Delivery Applications and Complementing Cell

Company developing next generation, disease-modifying, non-opioid analgesic gene therapies for the treatment of chronic painDELRAY BEACH, FL / ACCESSWIRE / May 23, 2023 / Adolore Biotherapeutics, Inc.

Related Keywords

Jenene Thomas ,Gewinn Nur ,University Of Pittsburg ,Adolore Biotherapeutics Inc ,University Of Pittsburgh ,Adolore Biotherapeutics Inc View ,Toxic Herpes Simplex Virus Vectors ,Efficient Gene Delivery Applications ,Complementing Cells ,Herpes Simplex Virus ,Carbonic Anhydrase Like Analgesic Peptides ,Orphan Drug ,Disease Modifying Anti Pain ,Inc View ,Adolore ,Iotherapeutics ,Centers ,Exclusive ,License ,Agreement ,University ,Pittsburgh ,Patents ,Protecting ,Toxic ,Replication ,Defective ,Sectors ,Efficient ,Gene ,Delivery ,Applications ,Complementing ,